Custom HIV vaccine trial shows promise in small study
NCT ID NCT00510497
First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-phase study tested a personalized vaccine for HIV made from each patient's own immune cells and virus. Eleven participants who had never taken HIV medication received the vaccine to see if it was safe and could lower their virus levels after a temporary break from treatment. The goal was to explore whether this approach could help control HIV without daily pills.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.